Close Menu

NEW YORK – With an influx of new funding, instrument vendor Atonarp is shifting its focus to its optical spectroscopy and clinical diagnostics business.

The Tokyo-based company announced this week that it closed a $33 million Series C funding round. According to Atonarp COO Dave Anderson, the firm plans to use the funds to support its existing mass spectrometry businesses, which primarily targets industrial and process control markets, and develop its nonlinear optical spectroscopy technology for biosensing and imaging applications.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.